

LEVOLET - (0.075MG,0.088MG,0.1MG,0.112MG,0.125MG,0.137MG,0.15MG,0.175MG,0.2MG,0.3MG ; Tablet)

Generic Name	LEVOTHYROXINE SODIUM	Innovator	Genus Life
Dosage	0.075MG,0.088MG,0.1MG,0.112MG,0.125MG,0.137MG,0.15MG,0.175MG,0.2MG,0.3MG ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	LEVOLET is levothyroxine sodium (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.